-
361
INTEGRATION OF EDUCATION, SCIENCE, AND BUSINESS: CURRENT INSTITUTIONAL SOLUTIONS
Published 2018-02-01Get full text
Article -
362
PANDEMIC OASIS: POPULAR RELIGIOSITIES AS WOMEN’S LIFE-GIVING COMMUNITAS
Published 2023-04-01Get full text
Article -
363
KANT ON JUSTICE
Published 2022-07-01“…First, I discuss how Kant’s conception of the moral law – its form as a categorical imperative, as the synthetic a priori basis of moral reasoning, operates initially as a limiting condition for the moral agent not to violate freedom and rights of one another. …”
Get full text
Article -
364
Experimental and Numerical Studies of Supercritical Water Flooding for Offshore Heavy Oil Recovery
Published 2022-01-01Get full text
Article -
365
Formal Analysis of Fairness for Optimistic Multiparty Contract Signing Protocol
Published 2014-01-01“…Furthermore, for solving or mitigating the state space explosion problem, we set a state reduction algorithm which can decrease the redundant states properly and reduce the time and space complexity greatly. …”
Get full text
Article -
366
Feasibility of Reprocessing Natural Fiber Filled Poly(lactic acid) Composites: An In-Depth Investigation
Published 2017-01-01Get full text
Article -
367
-
368
-
369
Foamy Melamine Resin–Silica Aerogel Composite-Derived Thermal Insulation Coating
Published 2025-01-01Get full text
Article -
370
Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
Published 2013-12-01Get full text
Article -
371
-
372
Improving the quality of cast metal of pipeline valves by modification of dispersed inoculators
Published 2018-07-01Get full text
Article -
373
-
374
Abdominal Pain as First Manifestation of New Coronavirus Infection COVID-19
Published 2020-12-01Get full text
Article -
375
-
376
-
377
-
378
Sensitivity and identifiability analysis of COVID-19 pandemic models
Published 2021-03-01Get full text
Article -
379
-
380
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Published 2025-02-01“…The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Foundation Medicine test (FoundationOneCDx) at TMB≥10 mut/Mb as a companion diagnostic (CDx) for single-agent pembrolizumab in second+line. …”
Get full text
Article